SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Post-COVID / Long-COVID

Interventions

DRUG: Placebo
BIOLOGICAL: Sipavibart

Sponsor

Nancy Klimas

Collaborators

[object Object]